Voyager Therapeutics (NASDAQ: VYGR) reported Q3 EPS of ($0.59), $0.01 worse than the analyst estimate of ($0.58). Revenue for the quarter came in at $4.61 million versus the consensus estimate of $2.91 million.

For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.